While monoclonal antibodies have achieved undoubted commercial success and qualified clinical success, there remain many unresolved issues to address in the design and development of an optimal monoclonal antibody therapeutics for the treatment of solid tumors.

There are four fundamental criteria to be considered in the advancement of an antibody-based therapeutic:

• Target: The entity to which the antibody binds
• Generation: The method by which the antibody is raised
• Mechanism: The manner in which the antibody will elicit efficacy
• Production: How the antibody will be manufactured

Viventia has developed innovative solutions and has built infrastructure and capabilities, that enable the Company to address each of these considerations. Viventia offers a comprehensive, integrated ‘bench to bedside’ R&D engine, capable of identifying new targets, developing human antibodies against those targets, optimizing those antibodies to have favorable therapeutic properties and producing those antibodies for use in clinical trials with a view to commercialization.

Viventia has conceived, built and successfully operationalized these platform technologies and now routinely isolates and screens hundreds of thousands of human monoclonal antibodies annually. This discovery engine has identified to date over 12 new cancer drug targets and their associated antibody drug leads.

Fully realized, this platform has the capability to effectively mine the human immune response to disease not only within cancer, but across the therapeutic spectrum, representing a novel, complementary adjunct to other antibody technologies, as well as an integrated, standalone ‘target to clinic’ engine.

UnLock™ - isolation and identification of membrane-associated tumor markers. Serves as engine for identification of known and novel cell-surface targets. Has identified 12 new potential cancer drug targets and continues to discover new targets at a rate of one to two per quarter.

Fusogenics™ - captures immune response of cancer patients in library format, which can be expressed as soluble recombinant protein and tested with functional assay. Isolates antibody responses of cancer patients and expresses them in a proprietary soluble functional library.

ImmunoMine™ - high-throughput antibody screening process that consists of a rapid screening ‘funnel,’ built upon increasingly more rigorous tests designed to rapidly sort therapeutically promising, tumor-specific antibodies from antibodies that react with normal cells.

Armed Antibodies™ - engineered antibody fragments (solid tumor penetration), recombinantly fused (stable conjugation) with potent tumor-activated cytotoxic proteins (optimal safety and efficacy).